Download Citation
Article Source:
The use of 18F-Fluoro-deoxy-glucose positron emission tomography (18F-FDG PET) as a non-invasive pharmacodynamic biomarker to determine the minimally pharmacologically active dose of AZD8835, a novel PI3Kα inhibitor
Maynard J,
Emmas SA,
Ble FX,
Barjat H,
Lawrie E,
et al.
(2017)
The use of 18F-Fluoro-deoxy-glucose positron emission tomography (18F-FDG PET) as a non-invasive pharmacodynamic biomarker to determine the minimally pharmacologically active dose of AZD8835, a novel PI3Kα inhibitor.
PLOS ONE 12(8): e0183048.
https://doi.org/10.1371/journal.pone.0183048